Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-10-28

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-editing medicines, led by approved CASGEVY and a pipeline spanning cardiometabolic, autoimmune, oncology, and regenerative programs.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved proof, broader platform still pending

The company has crossed the hardest credibility threshold with the first approved CRISPR therapy, but 2031 upside still depends on proving that wholly owned programs can become real businesses. Near-term repricing is unusually concentrated in a small set of November clinical readouts.

Analysis

Thesis

CRISPR Therapeutics already has first-product credibility and enough capital to fund multiple shots on goal; if CASGEVY keeps converting approvals into treated patients and one wholly owned in vivo or autoimmune program becomes commercially real by 2031, the stock can re-rate from cash-backed optionality to a multi-franchise gene-editing company.

Last Economy Alignment

AI should help target selection, edit design, and portfolio speed, while regulated trust, IP, and manufacturing keep value from collapsing into commodity software. But biology, regulators, and treatment-center logistics still dominate outcomes, so alignment is solid rather than extreme.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

This is not a priced-for-perfection story, but it is no longer a pure science option either. The market already pays for approved-platform credibility and runway. Upside comes from converting that credibility into one direct, wholly owned franchise and a steadier CASGEVY economic stream; downside is that the stock stays valued mainly on cash, milestones, and optionality.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not survival. CRISPR has enough balance-sheet support and real regulatory credibility, but the stock still needs broader validation beyond CASGEVY and enough direct economic capture from wholly owned programs to avoid remaining a partner-mediated, milestone-driven story.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Oct. 19 brought a CFO transition to internal successor A.J. Silver; continuity looks acceptable, but leadership turnover is now a watch item.
No new efficacy data arrived in the last 10 days, so the November zugo-cel and CTX310 presentations remain the dominant repricing gates.
Recent insider filings appear tied to the executive transition rather than a visible change in operating outlook.

Forecast update

Higher starting equity value without new efficacy proof modestly compresses forward return asymmetry; otherwise the setup is broadly similar.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

It owns real gene-editing know-how, manufacturing capability, and one approved therapy, so cheaper AI-driven discovery should help it find and design programs faster. But biology, regulators, and treatment-site logistics still decide value, so AI alone cannot force the growth curve.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$85.63

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research